SLC5A5 and triple-negative breast carcinoma: NIS expression is predominantly seen in ER-positive and also in some triple-negative breast cancer subtypes, and the molecular mechanisms affecting NIS have relocated it from the cytoplasmic location to the plasma membrane, unlike in the lactating breast [25].